BORTEZOMIB, LIPOSOMAL DOXORUBICIN AND DEXAMETHASONE REGIMEN FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND INTRODUCTION OF SERUM FREE LIGHT CHAINS (SFLC) IN RESPONSE MONITORING: PRELIMINARY DATA

被引：0
|
作者：
Pisani, F.
Cordone, I. [1 ]
Dessanti, M. L. [2 ]
Cigliana, G. [1 ]
Frollano, B. [1 ]
Masi, S. [1 ]
Mengarelli, A. [2 ]
Spadea, A. [2 ]
D'Andrea, M. [2 ]
Petti, M. C. [2 ]
机构：
[1] Ist Nazl Tumori Regina Elena, SC Patol Clin, Rome, Italy
[2] Ist Nazl Tumori Regina Elena, SC Ematol, Rome, Italy
来源：
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL | 2008年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1106
引用
收藏
页码：435 / 435
页数：1
相关论文
共 50 条
  • [31] A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    Hilger, James D.
    Klein, Leonard M.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert
    BLOOD, 2012, 120 (21)
  • [32] BORTEZOMIB, PEGYLATED LIPOSOMAL DOXORUBICIN AND DEXAMETHASONE (B-PEGHLD-D) AS THERAPY FOR PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOIVIA
    Gozzetti, A.
    Marchini, E.
    Fabbri, A.
    Bocchia, M.
    Defina, M.
    Lauria, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 437 - 437
  • [33] A Phase 1/2 Trial of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    Stampleman, Laura V.
    Bessudo, Alberto
    Rosen, Peter J.
    Klein, Leonard M.
    Woliver, Thomas
    Flam, Marshall S.
    Eshaghian, Shahrooz
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert
    BLOOD, 2014, 124 (21)
  • [34] A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma
    Schroeder, Mark A.
    Fiala, Mark A.
    Huselton, Eric
    Cardone, Michael H.
    Jaeger, Savina
    Jean, Sae Rin
    Shea, Kathryn
    Ghobadi, Armin
    Wildes, Tanya
    Stocked-Goldstein, Keith E.
    Vij, Ravi
    CLINICAL CANCER RESEARCH, 2019, 25 (13) : 3776 - 3783
  • [35] Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study
    Voorhees, Peter M.
    Gasparetto, Cristina
    Richards, Kristy L.
    Garcia, Reynaldo
    Strader, John S.
    Ferraro, Madlyn
    MacLean, Jennifer
    Winans, Diane
    Moore, Dominic T.
    Dodd, Andrew
    Foster, Matthew C.
    Gabriel, Don A.
    Shea, Thomas C.
    Serody, Jonathan
    van Deventer, Hendrik W.
    Rizvi, Syed
    Orlowski, Robert Z.
    Hurd, David D.
    BLOOD, 2009, 114 (22) : 129 - 130
  • [36] Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment
    Blade, Joan
    Sonneveld, Pieter
    Miguel, Jesus E. San
    Sutherland, Heather J.
    Hajek, Roman
    Nagler, Arnon
    Spencer, Andrew
    Robak, Tadeusz
    Cibeira, M. Teresa
    Zhuang, Sen H.
    Harousseau, Jean-Luc
    Orlowski, Robert Z.
    CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (06): : 352 - 355
  • [37] Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma
    Voorhees, Peter M.
    Gasparetto, Cristina
    Osman, Keren
    Richards, Kristy
    Ferraro, Madlyn
    Garcia, Reynaldo
    MacLean, Jennifer
    Winans, Diane
    Moore, Dominic
    Strader, John
    Orlowski, Robert Z.
    Hurd, David Duane
    BLOOD, 2010, 116 (21) : 815 - 816
  • [38] Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone
    Jagannath, Sundar
    Richardson, Paul G.
    Barlogie, Bart
    Berenson, James R.
    Singhal, Seema
    Irwin, David
    Srkalovic, Gordan
    Schenkein, David P.
    Esseltine, Dixie L.
    Anderson, Kenneth C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2006, 91 (07): : 929 - 934
  • [39] A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple myeloma patients
    Berenson, James R.
    Yellin, Ori
    Chen, Chien-Shing
    Patel, Ravi
    Bessudo, Alberto
    Boccia, Ralph V.
    Yang, Hank H.
    Vescio, Robert
    Yung, Elizabeth
    Mapes, Russell
    Eades, Benjamin
    Hilger, James D.
    Wirtschafter, Eric
    Hilger, Jacqueline
    Nassir, Youram
    Swift, Regina A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2011, 155 (05) : 580 - 587
  • [40] Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab ("Pom-PAD-Dara") in relapsed/refractory multiple myeloma
    Zhou, Xiang
    Steinhardt, Maximilian J.
    Grathwohl, Denise
    Meckel, Katharina
    Nickel, Katharina
    Leicht, Hans-Benno
    Krummenast, Franziska
    Einsele, Hermann
    Rasche, Leo
    Kortuem, Klaus M.
    CANCER MEDICINE, 2020, 9 (16): : 5819 - 5826
12345